RT Journal Article
SR Electronic
T1 Beneficial Effect of Interleukin 1 Inhibition with Anakinra in Adult-onset Still's Disease. An Open, Randomized, Multicenter Study
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP jrheum.111549
DO 10.3899/jrheum.111549
A1 Nordström, Dan
A1 Knight, Ann
A1 Luukkainen, Reijo
A1 van Vollenhoven, Ronald
A1 Rantalaiho, Vappu
A1 Kajalainen, Anna
A1 Brun, Johan G.
A1 Proven, Anne
A1 Ljung, Lotta
A1 Kautiainen, Hannu
A1 Pettersson, Tom
YR 2012
UL http://www.jrheum.org/content/early/2012/07/26/jrheum.111549.abstract
AB Objective To study the efficacy of anakinra versus disease-modifying antirheumatic drugs (DMARD) in refractory adult-onset Still’s disease (AOSD). Methods In a 24-week study, 22 patients with AOSD taking prednisolone ≥ 10 mg/day received anakinra (n = 12) or DMARD (n = 10). The primary endpoint was achievement of remission. Results At 8 and 24 weeks, 7/12 and 6/12 receiving anakinra and 5/10 and 2/10 receiving DMARD achieved remission. Anakinra induced greater improvement in physical health measured by Medical Outcomes Study Short-Form 36 (SF-36; p < 0.011). During an open-label extension (OLE) of 28 weeks, 7/14 patients taking anakinra and 2/3 taking DMARD were in remission. Conclusion Anakinra induced more beneficial responses than DMARD in patients with AOSD and was favored in the OLE phase. (ClinicalTrials.gov Protocol Registration NCT01033656).